Everolimus-based immunosuppression induces alloreactive regulatory T cell expansion combined with loss of alloreactive effector T cells.

Researchers randomly assigned organ-transplant recipients to an everolimus-based treatment plan or another anti-rejection plan. They examined alloreactive immune cells, meaning cells that react against the transplanted organ. Everolimus was linked to more regulatory T cells, which help calm immune attacks, and fewer effector T cells, which actively attack targets. The study measured these immune changes rather than whether people lived longer or aged more slowly.

What this means for you: This may help doctors understand how to manage transplant rejection, but it is not evidence that everolimus extends lifespan or benefits healthy people. Do not start, stop, or change this prescription without a transplant specialist.